![uniQure](https://www.statnews.com/wp-content/uploads/2020/12/AP_464867626358-645x645.jpg)
UniQure, the Dutch gene therapy company, said Monday that it had temporarily halted the clinical development of its hemophilia B treatment after a patient was diagnosed with liver cancer.
The clinical hold, mandated by the Food and Drug Administration, encompasses three ongoing studies of Uniqure’s hemophilia B gene therapy called etranacogene dezaparvovec. Patient dosing in all three studies had already been completed and there is no plan to enroll or treat new patients, the company said.
Shares of Uniqure fell 20% to $36 in early Monday trading.
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.